A Randomized, Open Label, Multicenter Phase III Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Camrelizumab (Primary) ; Famitinib (Primary) ; Carboplatin; Paclitaxel
- Indications Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms BCTOP-T-N01
Most Recent Events
- 19 Feb 2024 Status changed from not yet recruiting to recruiting.
- 23 Aug 2023 New trial record